Evidence map›Paper›PMID 38258119›Full record

ArticlePharmaceutics2024

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability.

Lili Wang, Zhuang Ding, Zhengping Wang, Yanna Zhao, Hengqian Wu, Qipeng Wei, Lingfeng Gao, Jun Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lili WangSchool of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.ORCID 0009-0000-7511-5484
Zhuang DingInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Zhengping WangInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Yanna ZhaoInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Hengqian WuSchool of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.
Qipeng WeiInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Lingfeng GaoSchool of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.
Jun HanSchool of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.

Funding

National Science and Technology Major Project 2017ZX09201-003The Open Project of Shandong Collaborative Innovation Center for Antibody Drugs CIC-AD1828The Taishan Scholar Research Fund of Shandong Province of China ts201511044
6 · The paper itself

Abstract

Paxlovid

Indexed as

bioavailabilityliquid formulationnirmatrelvirritonavirstability

Identifiers

PMID38258119
PMCPMC10818454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.